Follicular non-Hodgkin's lymphomas usually present in advanced stage and although frequently are chemotherapy-sensitive remain incurable using conventional approaches. Treatment options are evolving rapidly and now include targeted therapies such as monoclonal antibodies. Recent studies, including the EBMTR-sponsored 'CUP Trial' (conventional Chemotherapy, Unpurged autograft, Purged autograft), demonstrate that for patients under age 60 years with recurrent chemotherapysensitive disease, autologous stem cell transplantation (ASCT) provides a survival benefit over conventional therapy. Allogeneic stem cell transplantation (alloSCT) has become a more effective option. Although incorporation of TBI into the preparative regimen may increase treatment-related mortality (TRM), relapses appear to be reduced compared to a chemotherapy-alone regimen. Reduced-intensity alloSCT procedures are now being performed at an increasing rate, in part due to a lower risk for TRM. Until more data are available, however, reduced-intensity alloSCT should be considered only in cases where myeloablative conditioning is contra-indicated. There are no clear means for choosing ASCT vs alloSCT, a decision influenced by the amount of residual tumor, disease-responsiveness, degree of marrow involvement and extent of prior chemotherapy. ASCT or alloSCT in first remission remains an investigational procedure. Future considerations include incorporation of novel preparative regimens, in vitro purging techniques, antilymphoma vaccines, post transplant immunotherapy and ex vivo-manipulated donor lymphocyte infusions.
geneic stem cell transplantation; purging Follicular non-Hodgkin's lymphoma (NHL) comprises approximately one-third of all lymphomas with about 80% of patients having advanced-stage disease at diagnosis. 1 Paradoxically, this chemotherapy-sensitive disorder is generally incurable using conventional means. Median survivals are 8-10 years even in advanced-stage disease, but the annual mortality rate is approximately 6% per year. Prognosis of individual patients is difficult to predict, and use of prognostic scoring systems such as the Age-Adjusted International Prognostic Index (IPI) is of limited value although more recent data indicate that the Follicular Lymphoma International Prognostic Index (FLIPI) may be helpful. 2, 3 After initial treatment and first recurrence, the natural history of follicular NHL is a continuum of successive relapses of progressively shorter duration and ultimately death from the underlying disease. 4, 5 Conventional chemotherapy has limited or no impact on survival; immunotherapy with agents such as interferon likely has modest impact but often is poorly tolerated and therefore not widely used. [6] [7] [8] [9] Newer treatments such as the monoclonal antibodies rituximab, tositumomab (Bexxars) and ibritumomab tiuxetan (Zevalins) have excellent activity and a favorable side-effect profile. It will be years, however, before any impact on survival will become apparent. Highdose chemotherapy with autologous stem cell transplantation (ASCT) or allogeneic stem cell transplantation (alloSCT) represents an alternative treatment approach. Advantages of stem cell transplantation include the potential favorable impact upon survival, while disadvantages are toxicity and an adverse side-effect profile. 10 In this article, we will review the current status of ASCT and alloSCT for follicular NHL.
Autologous stem cell transplantation: indications and results

ASCT for recurrent disease
Conventional dose chemotherapy for the treatment of patients with recurrent follicular NHL is likely to produce remissions but of shorter duration each time. Several phase II studies suggest, however, that salvage treatment followed by consolidation with ASCT can prolong disease-free survival (DFS) in relapsed disease patients. Freedman et al 11 reported the largest single institution experience. A total of 153 patients were treated using autologous bone marrow purged in vitro with anti-B-cell monoclonal antibody. At a median follow-up of 5 (range 2-13) years, the 8-year DFS and overall survival (OS) were estimated as 42 and 66%, respectively. Table 1 lists the major phase II trials that showed similar results using different hematopoietic stem cell sources, ex vivo purging methods, highdose conditioning regimens and follow-up periods. [11] [12] [13] [14] [15] [16] [17] [18] [19] [20] [21] [22] [23] [24] [25] [26] [27] All trials suggested an improved median duration of PFS compared to historic controls treated with conventional chemotherapy; a fraction of patients attained prolonged PFS. On the other hand, with longer follow-up, recurrence rates of over 50% were generally observed and questions remain as to whether the durable responses were due to a treatment effect vs patient selection. Comparisons with historic controls suggesting that transplant results in improved survival were not entirely convincing. 19, 28 The EBMTR-sponsored CUP trial (conventional Chemotherapy, Unpurged autograft, Purged autograft) conducted between 1993 and 1997 is the only prospective, randomized trial to address the role of ASCT in prolonging PFS and OS in patients with follicular NHL. 24 Due to slow accrual, the trial was closed after enrollment of 140 of a planned 250 patients. In all, 65% of patients were in first relapse, the remainder in subsequent relapses. Patients were given three initial cycles of chemotherapy (usually a CHOP-like regimen) and 89 patients who attained at least a partial response were randomized to one of three treatment arms: further conventional chemotherapy, ASCT using purged and ASCT using unpurged autografts. Too few patients were entered to assess the effect of ex vivo purging. PFS and OS at 2 years after transplant for both patient groups randomized to ASCT were 55 and 71% compared to 26 and 46%, respectively, for those receiving conventional chemotherapy. 24 Hazard ratios for survival and PFS were 0.3 and 0.4, respectively, when comparing conventional chemotherapy with ASCT. These data are highly statistically significant and demonstrate that ASCT provides an important survival benefit in patients with chemosensitive recurrences of follicular NHL and currently should be considered a treatment of choice in this situation.
ASCT as consolidation of first remission
ASCT also has been used for low-grade NHL patients in first complete or partial remission in order to prolong or render such remissions permanent. Several phase II trials are summarized in Table 2 . 15, 26, [28] [29] [30] [31] [32] [33] [34] [35] [36] The trial reported by Freedman et al, 29 enrolled advanced disease stage patients who had responded to CHOP chemotherapy and underwent consolidation with Cy/TBI and ASCT. Although durable responses were observed, the investigators reported a continuous risk of disease recurrence. Horning et al 30 used a similar strategy, but described improved disease recurrence risk and survival after ASCT compared to a historic control group (30 vs 70% estimated 10-year risk of disease recurrence and 84 vs 62% estimated 10-year survival). Additionally, the results recently reported by Corradini et al 31 were similar. The encouraging phase II data summarized in Table 2 led several groups to develop multi-center, randomized studies comparing ASCT consolidation vs interferon maintenance or observation. The German Low Grade Lymphoma Study Group randomized chemosensitive indolent (mostly follicular) NHL patients younger than 60 years in first partial or complete remission to ASCT vs maintenance interferon therapy. 32 A total of 240 follicular NHL patients were evaluable for the comparison of ASCT vs interferon maintenance. At a median follow-up period of 4.2 years, 31 relapses (27.2%) were observed in the ASCT study arm and 76 (60.3%) in patients receiving IFN maintenance. In addition, five deaths occurred in remission (four patients in the ASCT study arm and one in the IFN group). Accordingly, the PFS was significantly different in the two study arms. In patients receiving ASCT, the PFS was 79.1% after 2 years (95% confidence interval 71. 33 This finding may be due to the fact that patients undergoing ASCT appeared at increased risk for the development of myelodysplastic syndrome (MDS). 37 In the absence of a demonstrated survival benefit, the data do not support ASCT in first remission for follicular NHL patients outside of a clinical trial.
Transformed follicular NHL
Over time a considerable percentage of follicular NHL patients develop disease transformation. Such patients are often treated in a manner similar to large cell NHL patients, but tend to have a poor prognosis and are considered incurable. Early reports indicated ASCT to be ineffective in this patient group. 38 Subsequently, improved patient selection resulted in better overall outcome and has led to ASCT as consolidation treatment after reinduction therapy. Table 3 illustrates several small studies indicating that consolidation with ASCT can induce durable remissions in some patients. 18, 22, 31, [39] [40] [41] [42] In fact, some larger retrospective analyses suggest a survival benefit of ASCT in the setting of transformation that might be comparable to results in nontransformed follicular NHL or diffuse large cell NHL. [41] [42] [43] For example, in the case-matched report from the EBMTR, a subgroup of patients with chemosensitive minimal residual disease prior to an ASCT had an overall 5-year survival of 69%. 41 
Technical considerations
Several technical aspects of ASCT such as choice of hematopoietic stem cell source, ex vivo purging, conditioning regimen and aspects of supportive care may have a considerable influence on the outcome of transplant and ideally should be investigated in prospective, randomized studies. For a variety of reasons, including the large number of patients required, considerable expense of such an undertaking and requirement for prolonged follow-up, Early TRM ¼ treatment-related mortality occurring in the first year after transplant. For other abbreviations, see Table 1 footnote. 23 in the IBMTR noted nearly a two-fold lower TRM in the 553 patients who received a non-TBI preparative regimen compared to the 348 subjects given TBI (P ¼ 0.008). On the other hand, TBI in the preparative regimen was associated with a statistically significant decrease in the rates of disease recurrence (P ¼ 0.02).
These observations, while far from definitive, suggest that TBI is a particularly effective, but a rather toxic treatment for follicular lymphoma and provide a rationale for the further development of radio-labeled monoclonal antibodies as part of conditioning regimens for transplant. 44 In a single-center, phase II study reported by Gopal et al, 45 98 individuals with follicular lymphoma transplanted using conventional-dose ASCT (70% received a TBI-containing regimen) were compared to 27 patients transplanted using high-dose chemotherapy and radioimmunotherapy ( 131 Ianti-CD20 monoclonal antibody, tositumomab). The estimated 5-year OS and PFS were 67 and 48%, respectively, for those subjects given radioimmunotherapy conditioning compared to 53 and 29%, respectively, for conventional ASCT. Further, 100-day TRM was only 3.7% in the radioimmunotherapy group vs 11% in the conventional group; both groups had similar probabilities of secondary MDS/AML. Interesting preliminary data regarding the use of 186 rhenium-labeled anti-CD20 followed by autogous stem cell rescue recently were reported by a German Group. 46 
In vitro purging
Most patients with follicular NHL present in advanced disease stage and often with morphologic evidence of marrow involvement. 47 Even in patients with histologically normal marrow, occult marrow involvement can usually be demonstrated by PCR technique. 48 It is likely that these lymphoma cells contaminating the stem cell infusate contribute to relapse after ASCT. While direct evidence for this hypothesis is lacking, several lines of indirect evidence support this concept. First, several groups have demonstrated that presence of occult stem cells in the graft correlates with risk of disease recurrence. 49 54, 55 Ex vivo technologies to decrease tumor contamination include 'positive' selection, 56 that is, the in vitro enrichment of the graft for CD34 cells, a marker presumably lacking on lymphoma cells, as well as 'negative' selection, that is, the removal of tumor cells by exposure to lymphoma-specific antibodies. 50, 51, 57 These methods have been extensively investigated and several phase II studies suggest that effective purging is of clinical benefit. For example, the group from the Dana Farber Cancer Institute found that successful in vitro purging was associated with dramatically improved freedom from relapse in follicular NHL patients undergoing ASCT. 11, 29 Furthermore, Ladetto et al 52 showed that successful in vivo purging (ie the generation of PCR-negative harvests after intensive induction chemotherapy) was associated with improved PFS. Fouillard et al, 50 using various purging methods, also found a correlation between ex vivo graft treatment and outcome. Only one group failed to find a correlation between PCR status of the infusate and recurrence. 14 The obvious corollary of these findings is that occult lymphoma cells contribute to recurrence in tumor-contaminated grafts. The absence of a satisfactory control group in these studies, however, makes it impossible to rule out the alternative explanation, namely that the ability to achieve a tumor-free graft is a surrogate for chemotherapy sensitivity. The CUP trial attempted to address this issue in a prospective fashion, but low patient numbers limited the study's power. 24 The best, albeit indirect, evidence concerning the role of a tumor-free graft comes from several registry analyses. A case-control study from EBMTR demonstrated an improved PFS in patients given purged rather than unpurged autografts for follicular NHL. 58 A group of 270 patients given purged (marrow) ASCT were compared to 224 casematched unpurged (marrow) ASCT patients. Patients with low-grade NHL did not have a significantly improved PFS if the bone marrow was purged (P ¼ 0.1757); however, they did have a significantly improved OS (P ¼ 0.00184). This increased OS was found to be associated with non-TBI conditioning and also with the purged patients undergoing transplantation at large transplant centers (P ¼ 0.0016). More recently, a retrospective IBMTR study identified stem cell purging as an independent predictor for relapse, PFS and OS (P ¼ 0.03) in multivariate analysis. 23 The hazard ratio for disease recurrence after purged transplant was 75% of that after unpurged transplantation. Third, a casecontrol study by Bierman et al 59 comparing syngeneic transplants, purged ASCT and unpurged ASCT showed that syngeneic transplants had a very low recurrence rate. When compared with syngeneic transplants, unpurged ASCT had a significantly higher (nearly five-fold) risk of relapse (P ¼ 0.008); recipients of purged ASCT had a threefold higher relapse risk than syngeneic transplant recipients, but this difference was not statistically significant (P ¼ 0.10). 59 We interpret these data as indicative of the importance of providing a tumor-free graft.
Current technology limits the efficiency of graft purging. For example, in the Dana-Farber series, persistent marrow involvement could be detected in almost half the patients after negative selection with a panel of monoclonal antibodies. 11, 29 In addition to positive and negative in vitro selection, in vitro chemotherapy exposure has been used for purging of stem cells. 50 This technique, while of historic and perhaps clinical interest, has fallen out of favor because of its complexity, the associated nonselective damage to normal progenitors and the subsequent delay in hematopoietic recovery after graft re-infusion. More recently, rituximab has also been used as an 'in vivo purging' agent. Pilot studies indicate that rituximab administration may eliminate PCRdetectable cells in a significant proportion of hematopoietic cell harvests but may be associated with late neutropenia and serious infection. [60] [61] [62] Whether transplant outcome will be improved by collecting PBSC after exposure to rituximab remains to be demonstrated. Several novel purging technologies are currently undergoing early evaluation. For example, the anti-CD133 monoclonal antibody targets a primitive stem cell population and is being evaluated for positive stem cell selection. 63 Others are using pulsed electric fields to deplete tumor cells from a graft selectively. 64 
Late toxicites of ASCT: MDS and treatment-related leukemia
Although early morbidity is considerable, advances in supportive care significantly reduced the immediate treatment-related mortality associated with ASCT, even in elderly patients. On the other hand, late treatment-related side effects, such as MDS or secondary acute myeloid leukemia (sAML), occur at a 5 to 15-fold increased incidence. 65, 66 The etiology of post transplant MDS is complex and is related to a combination of host-related factors, prior treatment and conditioning. Micallef et al 67 reported upon 230 follicular NHL patients given cyclophosphamide and TBI followed by ASCT. At a median followup of 6 years, 27 (12%) developed therapy-related MDS or AML 4.4-8.8 years after transplant; prior fludarabine therapy (P ¼ 0.009) and older age (P ¼ 0.02) were associated with the development of the secondary malignant processes. Others have related the risk of secondary MDS to pretransplant treatment with etoposide or radiation 68 or to pretransplant exposure to mechlorethamine or chorambucil. 69 Excessive doses of radiation in the conditioning regimen may also be associated with increased risk for secondary MDS. 69 Interestingly, some studies have shown that clonal chromosomal abnormalities can often be detected in the graft of patients who have developed MDS after transplant 70, 71 The outcome for patients who develop treatment-related MDS/AML is usually is quite poor.
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Allogeneic stem cell transplantation
Myeloablative transplantation
The exact role of alloSCT in follicular NHL remains somewhat difficult to define. AlloSCT was initially used in patients thought not candidates for ASCT due to the extent of disease or marrow involvement; investigators believed that the allogeneic or graft-versus-tumor effect would eradicate disease via adoptive immunotherapy. [74] [75] [76] [77] [78] [79] [80] [81] [82] Several retrospective studies suggest that alloSCT is associated with a very low relapse rate and might be a curative treatment for follicular NHL (Table 4) 23,77-82 but that the benefit of alloSCT is at least partially offset by high TRM. The IBMTR reported data on 904 follicular NHL patients who during the period 1990 and 1999 underwent either ASCT or alloSCT. 23 A total of 176 (19%) patients underwent alloSCT, 131 (14%) were given purged ASCT and 597 (67%) received unpurged ASCT. The 5-year TRM rates were 30, 14, and 8% and recurrence rates were 21, 43, and 58% after alloSCT purged ASCT, and unpurged ASCT, respectively. Furthermore, the 5-year probabilities of survival were 51, 62, and 55% after alloSCT, purged ASCT and unpurged ASCT. 23 This communication confirms the high TRM yet low recurrence rate associated with the use of alloSCT and overall similar long-term patient survivals compared to ASCT. These data do not allow practitioners to make decisions for individual patients regarding the use of alloSCT vs ASCT; such treatment recommendations continue to be guided by physician judgment. Over the past decade, advances in supportive care and better patient selection have resulted in improved outcomes for alloSCT (Figure 1) . 23 Also, the risk of secondary MDS after alloSCT is negligible. We currently recommend alloSCT as the preferred therapy for recurrent NHL patients who are aged 50 years or less and who have an HLA-identical sibling donor. Use of a TBI-based conditioning regimen may be preferred due to the decreased recurrence rate associated with that modality.
Reduced-intensity transplantation
Reduced-intensity conditioning regimens, considered less toxic, are being used at increased frequency. The underlying hypothesis of such a strategy is that fewer patients will develop TRM and graft-versus-lymphoma effects will result in curing a greater percentage of patients. Interesting preliminary results indicate that this premise may be the case (Table 5) . 83 86 reported that two poorrisk, relapsed low-grade NHL patients failing T-celldepleted sibling-matched allografts re-entered durable complete remission after DLI from the original donors. Still, the considerable risks and toxicity associated with chronic GVHD cannot be underestimated and long-term follow-up on such studies is lacking. Robinson et al 85 reported preliminary results of an EBMTR analysis of nonmyeloablative transplantation in lymphoma. The lowgrade NHL patients had a disappointing 39% TRM and 29% PFS at 1 year after transplant, to a large extent due to GVHD and opportunistic infections. Paradoxically, some of the best reported results involve in vivo or in vitro T-celldepleted transplants such as the recent experience of using BEAM-alemtuzumab reduced-intensity alloSCT in which 70% of low-grade NHL patients are alive at 4 years. 84 The role of reduced-intensity alloSCT hopefully will be established by a recently activated trial conducted by the Blood and Marrow Transplant Clinical Trials Network comparing ASCT vs alloSCT in follicular NHL patients.
Future directions
The limitations of ASCT transplantation include disease recurrence and risk of secondary MDS. Future improvements are likely to focus on incorporation of targeted monoclonal antibodies into the preparative regimen and post transplant period, novel stem cell purging strategies and use of anti lymphoma vaccines or other forms of therapy in the post transplant period. These studies will be carried out in patients with recurrent disease and, if successful, could be extrapolated for use earlier in the course of the disease. Studies in alloSCT will focus on minimizing treatment-related complications that likely will include newer GVHD prevention approaches, use of new graft-versus-lymphoma maneuvers and incorporation of more advanced techniques of donor lymphocyte infusion (Table 6 ). 
